Ilex Medical

Ilex Medical Current Liabilities

The Current Liabilities of Ilex Medical (ILX.TA) as of Oct 23, 2026 is 267.87 M ILS. In the previous year, Current Liabilities was 311.29 M ILS — a change of -13.95% (lower).

Current Liabilities

267.87 MILS

YoY

-13.95%

Last updated:

Current Liabilities of Ilex Medical is 2024 267.87 M ILS. Current Liabilities of Ilex Medical was 2023 311.29 M ILS. It decreases by -13.95% lower compared to the previous year.

The Ilex Medical Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
156.93 M ILS
Jan 1, 2018
187.25 M ILS
Jan 1, 2019
189.35 M ILS
Jan 1, 2020
279.22 M ILS
Jan 1, 2021
240.11 M ILS
Jan 1, 2022
225.83 M ILS
Jan 1, 2023
311.29 M ILS
Jan 1, 2024
267.87 M ILS
The Ilex Medical Current Liabilities history
YEARCurrent LiabilitiesYoY
267.87 MILS-13.95%
311.29 MILS+37.84%
225.83 MILS-5.95%
240.11 MILS-14.01%
279.22 MILS+47.47%
189.35 MILS+1.12%
187.25 MILS+19.33%
156.93 MILS-5.25%
165.62 MILS+21.12%
136.75 MILS+933.63%
13.23 MILS-92.62%
179.34 MILS+5.43%
170.10 MILS-16.49%
203.70 MILS+198.24%
68.30 MILS+8.07%
63.20 MILS+8.78%
58.10 MILS+4.68%
55.50 MILS+9.47%
50.70 MILS-8.32%
55.30 MILS+62.17%
34.10 MILS+10.00%
31.00 MILS+25.51%
24.70 MILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ilex Medical Stock analysis

What does Ilex Medical do? Ilex Medical Ltd supplies in vitro diagnostic equipment and laboratory management software, targeting healthcare providers and laboratories. The company offers nucleic acid testing (NAT) blood screening solutions, cancer screening products, retro virus load monitoring, TB and STD testing systems, and blood sugar monitoring devices. Its subsidiaries include Ilex South Africa, Orsyx-LIS, Ilex BioTech Ltd, and Medtechnica Ltd, which support its diagnostic equipment and software distribution. Healthcare facilities and diagnostic laboratories purchase these products for clinical testing and patient management. Ilex Medical Ltd's revenue streams come from selling diagnostic equipment, reagent systems, and laboratory information systems (LIS) to healthcare institutions. The firm's NAT blood screening solutions and infectious disease testing systems are key products for blood banks and public health labs. Subsidiaries like Orsyx-LIS provide specialized laboratory management software, enhancing the company's offerings in the diagnostic software segment. Hospitals and clinics rely on these solutions for efficient diagnostic workflows. The company serves segments including hospitals, blood banks, public health laboratories, and clinics focused on infectious disease management. Products such as cancer screening tools and retro virus load systems are sold to specialized medical facilities. Ilex South Africa and Medtechnica Ltd extend the company's reach in regional markets, supporting localized sales and service. Diagnostic software from Orsyx-LIS is integrated into laboratory workflows for improved data management. Ilex Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ilex Medical stock

Current Liabilities of Ilex Medical is 267.87 M ILS in 2024.

Current Liabilities of Ilex Medical changed from 311.29 M ILS to 267.87 M ILS, representing a -13.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Ilex Medical since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Ilex Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ilex Medical

All Key Metrics — Ilex Medical